🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effectiveness and Adoption of the TelTex4BP Intervention Among Adults With Hypertension in Nepal

RecruitingNAAges 18 Years - 70 YearsAllCentral Department of Public Health
NCT05979168 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Despite evidence of preventing cardiovascular disease (CVD) risk through lifestyle changes, many patients with hypertension (HTN) do not comply with this and suffer from CVD and other complications. A previous study using a structured lifestyle intervention program has reported a 14% decrease in the 10-year risk of developing CVD at one year among hypertensive and diabetes patients. Low and Middle-Income countries (LMICs) struggle with a shortage of health workers to deliver such interventions. In this context, mobile phones can contribute to bridging this gap by incorporating them into the health system for health intervention delivery. There is a need to develop contextual mHealth intervention adapted to local needs and culture and test its effectiveness in LMIC settings like Nepal. Our previous small-scale pilot mHealth (text messages) study reported promising evidence in reducing blo

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Clinical diagnosis of hypertension * Currently receiving/prescribed blood pressure-lowering medication for more than three months * With uncontrolled blood pressure (\>130/80mm of Hg) * Should have access to a mobile phone * Able to read text messages ( by themselves/with the help of family) Exclusion Criteria: * Diagnosed with myocardial infarction, stroke, and kidney failure * Severe mental illness, cognitive impairment * Pregnant women or in the postpartum period
💊

What it tests

  • Phone call and text Messages
📍

Where

2 sites
Sahid Gangalal National Heart Center
Kathmandu, Nepal
Apara Innovations Pvt Ltd
Kathmandu, Nepal
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy